Back to Products
Ovarian Cancer CDO1 / HOXA9 dual-gene methylation
CISOVA®
A single blood draw to detect early ovarian cancer
CDO1/HOXA9 dual-gene methylation test requiring only a single peripheral blood ctDNA draw — non-invasive auxiliary diagnosis, solving the challenge of early detection of the 'silent killer.'
NMPA Registration
国械注准 20253402443
Date Approved
2025.12
Clinical Data
Robust clinical data support
Based on multi-center registered clinical trials, sensitivity and specificity both reach industry-leading levels.
Sensitivity (Ovarian Cancer)93.19%
Registered clinical trial
Specificity92.78%
Registered clinical trial
1,421cases
Registered clinical samples
≈10Kreal-world cases
Multi-center study
Peripheral blood cell-free DNA (non-invasive sampling)
Sample Type
Target Population
Who needs this test?
- Benign/malignant differentiation for women with ovarian cysts or pelvic masses
- Early risk assessment for high-risk ovarian cancer populations
- Ovarian health screening for peri- and postmenopausal women
- Auxiliary diagnosis for suspected ovarian cancer patients
Clinical Scenarios
How is it applied clinically?
- Non-invasive early screening for ovarian cancer
- Benign/malignant stratification of pelvic masses to aid surgical decisions
- Follow-up monitoring for high-risk ovarian cancer populations
- Women's cancer screening programs at health checkup centers
Highlights
Why choose us
01
China's first approved ovarian cancer methylation test product
02
Requires only a single blood draw with excellent patient compliance
03
ctDNA-based epigenetic testing — non-invasive and precise
04
Global patents and proprietary intellectual property
Evidence
Ovarian Cancer Related Publications
Standardized Application
